|
Active substance |
darolutamide |
|
Holder |
Bayer |
|
Status |
closed |
|
Indication |
treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease |
|
Public documents |
|
|
Last update |
09/08/2022 |